PCI Biotech invites to a presentation of the company's fourth quarter and preliminary 2018 report NewsKristin EivindvikFebruary 6, 2019
Preliminary confirmation of safety read-out from the fimaChem Phase I extension study in bile duct cancer NewsKristin EivindvikDecember 20, 2018
Extension of preclinical research collaboration agreement with a top-10 large pharma company NewsKristin EivindvikDecember 18, 2018
Last day of trading in subscription rights Monday 1 October 2018 NewsKristin EivindvikSeptember 28, 2018
Mandatory notification regarding exercise and trade of subscription rights NewsKristin EivindvikSeptember 20, 2018
Mandatory notification regarding exercise and trade of subscription rights NewsKristin EivindvikSeptember 20, 2018
Key information relating to the preferential rights issue to be carried out by PCI Biotech Holding ASA NewsKristin EivindvikAugust 24, 2018
